I'm more concerned about competition becoming entrenched in COVID therapy before we can complete our trials than I am about our trials showing efficacy. I do think that going for more numbers instead of unblinding early was the right call. I just wish we weren't so outgunned by BP when it comes to having many more sites to enroll patients.
Good ol' Cytodyn and our timelines making me agitated again.